Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Guardant Health Inc (NQ: GH )

28.61 +0.02 (+0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 8, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Guardant Health Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360® Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Hepion Pharmaceuticals (NASDAQ:HEPA 
Via Benzinga
Return on Capital Employed Insights for Guardant Health
After pulling data from Benzinga Pro it seems like during Q2, Guardant Health's (NASDAQ:GH) reported sales totaled $92.10 million. Despite a 9.48% in earnings, the company posted... 
Via Benzinga
Guardant Health Expands Precision Oncology Offerings
Guardant’s Q2 revenues grew 39% over the year to $92.1 million, ahead of the Street’s forecast by 8.8%. On an adjusted basis, it reported a loss of $0.96 per share, falling below the Street’s estimates... 
Via Talk Markets
Analyzing Guardant Health's Unusual Options Activity
Guardant Health (NASDAQ:GH) shares experienced unusual opti... 
Via Benzinga
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit
From Guardant Health, Inc.
Via Business Wire
Guardant Health, inc (GH) Q2 2021 Earnings Call Transcript
GH earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates
After the market close on Thursday, Guardant Health Inc (NASDAQ: GH) reported Q2 revenues increased 39% Y/Y to $92.1 million, beating the consensus of $84.61... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Sensus Healthcare (NASDAQ:SRTS) ... 
Via Benzinga
Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors
From Guardant Health, Inc.
Via Business Wire
The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 5) Alkermes plc (NASDAQ: ALKS)... 
Via Benzinga
Guardant Health Reports Second Quarter 2021 Financial Results
From Guardant Health, Inc.
Via Business Wire
Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic
From Guardant Health, Inc.
Via Business Wire
Guardant Health to Report Second Quarter Financial Results on August 5, 2021
From Guardant Health, Inc.
Via Business Wire
This Explosive Biotech Is Taking On a Huge New Market
Dominant in its core reproductive health market, niche medical diagnostics company Natera now has its sights on the crowded oncology diagnostics space. 
Via The Motley Fool
The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 29) 10x Genomics, Inc. (NASDAQ... 
Via Benzinga
Guardant Health Expands Guardant360® Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling
From Guardant Health, Inc.
Via Business Wire
Guardant Health Insights: Return On Capital Employed
During Q1, Guardant Health's (NASDAQ:GH) reported sales totaled $78.67 million. Despite a 18.31% in earnings, the company posted a loss of $107.86 million. Guardant Health... 
Via Benzinga
CORRECTING and REPLACING Study Shows Guardant Reveal™ Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity
From Guardant Health
Via Business Wire
CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers
From Guardant Health, Inc.
Via Business Wire
Cathie Wood, Bullish On SpaceX Partner Velo3D, Buys More SPFR Shares, Adds Vertex On Dip
Cathie Wood-led Ark Investment Management on Friday bought 25,000 shares, estimated to be worth about $250,000, in Jaws Spitfire Acquisition Corp (NYSE: SPFR), the blank-check... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer
From Guardant Health, Inc.
Via Business Wire
Guardant Health: Return On Capital Employed Insights
In Q1, Guardant Health (NASDAQ:GH) posted sales of $78.67 million. Earnings were up 18.31%, but Guardant Health still reported an overall loss of $107.86 million. Guardant Health... 
Via Benzinga
Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer
From Guardant Health, Inc.
Via Business Wire
Cathie Wood Buys $10.5M In Google, Loads Up Another $31.6M In Zoom
Cathie Wood-led Ark Investment Management on Thursday bought 4,496 shares, estimated to be worth about $10.55 million, in Google parent Alphabet Inc (NASDAQ: GOOGL) (NASDAQ: GOOG... 
Via Benzinga
Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer
The FDA has given accelerated approval to Amgen Inc's (NASDAQ: AMGN) Lumakras (sotorasib) for non-small cell lung cancer (NSCLC) patients harboring kras... 
Via Benzinga
Exposures Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021
Upgrades According to B of A Securities, the prior rating for Bloom Energy Corp (NYSE:BE) was changed from Underperform to Neutral. For the first quarter, Bloom Energy had... 
Via Benzinga
Guardant360® CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen’s LUMAKRAS™ (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer
From Guardant Health, Inc.
Via Business Wire
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.